Cytostatic treatment with irinotecan liposomal in a patient with advanced pancreatic adenocarcinoma Case report

Article Sidebar

PDF


Published: Jun 30, 2021
DOI: https://doi.org/10.24292/01.OR.122280621
Keywords:
pancreatic adenocarcinoma, liposomal irinotecan, chemotherapy

Main Article Content

Przemysław Będkowski
1. Department of Clinical Oncology, Chemotherapy, Clinical Research, Provincial Specialist Hospital in Slupsk. 2. Department of Daily Chemotherapy, Provincial Hospital in Koszalin
Wojciech Rogowski
1. Department of Clinical Oncology, Chemotherapy, Clinical Research, Provincial Specialist Hospital in Slupsk. 2. Pomeranian Academy in Slupsk

Abstract

Pancreatic cancer is one of the most common malignant neoplasms with a short survival time and a low cure rate. This neoplasm progresses quickly, it is often diagnosed in the advanced stage, which means that systemic treatment regimens are not sufficiently effective. A case of 65-year-old patient with metastatic pancreatic cancer who underwent sequential chemotherapy with the use of liposomal irinotecan was presented.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Article Details

How to Cite
1.
Będkowski P, Rogowski W. Cytostatic treatment with irinotecan liposomal in a patient with advanced pancreatic adenocarcinoma. OncoReview [Internet]. 2021Jun.30 [cited 2024Nov.22];11(2(42):40-3. Available from: https://journalsmededu.pl/index.php/OncoReview/article/view/1444
Issue
Vol 11 No 2(42) (2021)
Section
PERSONALIZED ONCOLOGY
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Copyright: © Medical Education sp. z o.o. This is an Open Access article distributed under the terms of the Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). License (https://creativecommons.org/licenses/by-nc/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.

Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)

References

1. Wojciechowska U, Didkowska J. Zachorowania i zgony na nowotwory złośliwe w Polsce. Krajowy Rejestr Nowotworów, Narodowy Instytut Onkologii im. Marii Skłodowskiej-Curie – Państwowy Instytut Badawczy (access: 1.02.2021).
2. Wang-Gillam A, Hubner RA, Siveke JT et al. NAPOLI-1 phase 3 study of liposomal irinotecan in metastatic pancreatic cancer: Final overall survival analysis and characteristics of long-term survivors. Eur J Cancer. 2019; 108: 78-87.
3. Taieb J, Abdallah R. How I treat pancreatic cancer. ESMO Open. 2020; 4(suppl 2): e000818. http://doi.org/10.1136/esmoopen-2020-000818.
4. Charakterystyka produktu leczniczego INN-Paklitaxel.
5. Conroy T, Desseigne F, Ychou M et al. FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer. N Engl J Med. 2011; 364: 1817-25. http://doi.org/10.1056/NEJMoa1011923.